Rafael Holdings, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On October 28, 2026, Rafael's subsidiary Cyclo Therapeutics submitted an NDA to the FDA for remibetadex (Trappsol Cyclo) for Niemann-Pick Disease Type C. The Phase 3 TransportNPC study did not meet its primary endpoint in the overall population (p=0.19) but showed 71% slowing of disease progression in a prespecified subgroup receiving background therapy (p=0.046) and 85% mortality reduction vs. registry controls. The NDA qualifies for a Rare Pediatric Disease Priority Review Voucher.
Why this rating
NDA submission is pivotal inflection for $38.6M company; lead asset clears major regulatory gate. Missed primary endpoint material risk, but subgroup data and survival benefit provide approval pathway. Voucher monetization potential valuable, though still regulatory-contingent.
Price action (we called it positive)
before filing · preread $1.14 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.